
Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target
Iovance Biotherapeutics (IOVA) Analyst Ratings
Bulls say
Iovance Biotherapeutics Inc. is poised for significant growth, underscored by its projected revenue for FY25, which is expected to range between $450 million and $475 million, fueled by increased demand and strategic efforts to enhance community referrals. The company's recent quarterly revenue results demonstrated a robust year-over-year increase, with 4Q24 revenue reaching $73.7 million, reflecting a strong performance in Amtagvi and Proleukin products. Moreover, with management forecasting gross product margins to exceed 70% in the coming years and a cash burn projected to remain under $300 million in 2025, Iovance is well-positioned to capitalize on its therapeutic advancements and market presence in the oncology space.
Bears say
Iovance Biotherapeutics Inc. faces a challenging financial outlook primarily due to higher-than-anticipated cash burn rates and difficulties in securing necessary capital for product launches and achieving commercial profitability. Projections for revenue growth appear dim, as reported earnings indicate a potential miss in 2025, alongside concerns about regulatory approvals beyond post-checkpoint melanoma that could further strain financial estimates. Additionally, potential setbacks related to clinical efficacy in various cancer types and the company's history of manufacturing challenges could lead to downward revisions of projections and greater financial instability.
This aggregate rating is based on analysts' research of Iovance Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
Iovance Biotherapeutics (IOVA) Analyst Forecast & Price Prediction
Start investing in Iovance Biotherapeutics (IOVA)
Order type
Buy in
Order amount
Est. shares
0 shares